Anavex Life Sciences (AVXL) vs. Medgenics (GNMX) Financial Contrast

Anavex Life Sciences (NASDAQ: AVXL) and Medgenics (NASDAQ:GNMX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, institutional ownership, earnings, risk and profitability.

Risk & Volatility

Anavex Life Sciences has a beta of 1.05, meaning that its share price is 5% more volatile than the S&P 500. Comparatively, Medgenics has a beta of 1.06, meaning that its share price is 6% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Anavex Life Sciences and Medgenics, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Anavex Life Sciences 0 0 3 0 3.00
Medgenics 0 1 1 0 2.50

Anavex Life Sciences currently has a consensus target price of $8.67, indicating a potential upside of 201.97%. Medgenics has a consensus target price of $4.25, indicating a potential upside of 108.33%. Given Anavex Life Sciences’ stronger consensus rating and higher probable upside, equities analysts clearly believe Anavex Life Sciences is more favorable than Medgenics.


This table compares Anavex Life Sciences and Medgenics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Anavex Life Sciences N/A -69.24% -62.66%
Medgenics N/A -163.88% -130.14%

Valuation & Earnings

This table compares Anavex Life Sciences and Medgenics’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Anavex Life Sciences N/A N/A -$13.46 million ($0.34) -8.44
Medgenics N/A N/A -$41.90 million ($0.96) -2.12

Anavex Life Sciences is trading at a lower price-to-earnings ratio than Medgenics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

22.8% of Anavex Life Sciences shares are held by institutional investors. Comparatively, 20.5% of Medgenics shares are held by institutional investors. 12.1% of Anavex Life Sciences shares are held by company insiders. Comparatively, 15.2% of Medgenics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.


Anavex Life Sciences beats Medgenics on 8 of the 11 factors compared between the two stocks.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases. The Company’s SIGMACEPTOR Discovery Platform produced small molecule drug candidates with unique modes of action. Sigma receptors may be targets for therapeutics to combat many human diseases, including Alzheimer’s disease. When bound by the appropriate ligands, sigma receptors influence the functioning of multiple biochemical signals that are involved in the pathogenesis (origin or development) of disease.

Medgenics Company Profile

Aevi Genomic Medicine, Inc., a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. Its lead product candidates include AEVI-001, a glutamatergic neuromodulator, which is in Phase II/III SAGA trial for a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients with specific mutations in their metabotropic glutamate receptor gene network; and AEVI-002, an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohn’s disease. The company was formerly known as Medgenics, Inc. and changed its name to Aevi Genomic Medicine, Inc. in December 2016. Aevi Genomic Medicine, Inc. was founded in 2000 and is based in Wayne, Pennsylvania.

Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with's FREE daily email newsletter.

Leave a Reply